AYTU BIOSCIENCE, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. (trading symbol: AYTU) on November 12, 2019, covering events occurring between November 1, 2019, and November 11, 2019. The company is incorporated in Delaware and lists its common stock on The Nasdaq Capital Market.
Key Financial Metrics and Liquidity
The filing addresses stockholders' equity levels required for Nasdaq compliance (Rule 5550(b), minimum $2.5 million). As of September 30, 2019, the company's stockholders' equity fell below this threshold. The deficiency was remediated through two primary capital events:
- Equity Financing: On October 13, 2019, the company completed an offering raising approximately $9.3 million.
- Asset Acquisition Financing: On November 1, 2019, the company issued approximately 9.8 million shares of Series G Convertible Preferred Stock, valued at an initial estimate of $5.6 million, to acquire a portfolio of commercial pediatric pharmaceutical assets and related workforce from Cerecor, Inc.
Following these transactions, the company's stockholders' equity balance exceeded the $2.5 million minimum requirement.
Material Changes and Corporate Actions
The primary material change reported is the restoration of compliance with Nasdaq listing standards regarding stockholders' equity. Additionally, the company executed a strategic acquisition of commercial pediatric pharmaceutical assets from Cerecor, Inc., funded through the issuance of preferred stock. This acquisition also included the transfer of a related workforce.
Management Commentary and Personnel Changes
On November 11, 2019, the company announced the appointment of Mr. Matthew Phillips as Executive Vice President of Commercial Operations, effective November 8, 2019. Mr. Phillips, formerly the Chief Commercial Officer at Cerecor, Inc., will lead commercial operations including sales, national accounts, and supply chain. He reports directly to Joshua R. Disbrow, the Chairman and CEO. The company proactively contacted Nasdaq to disclose the temporary non-compliance and subsequent remediation.
Investor Verification Checklist
- Verify the final audited stockholders' equity balance in the upcoming Form 10-Q for the period ended September 30, 2019.
- Confirm the terms and conversion features of the 9.8 million Series G Convertible Preferred Stock shares issued for the Cerecor acquisition.
- Review the details of the acquired pediatric pharmaceutical asset portfolio and the integration of the Cerecor workforce.
- Monitor the company's cash burn rate and runway following the $9.3 million equity raise and the asset acquisition.